New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
UP AFTER EARNINGS: Ulta Salon (ULTA), up 6%... Ebix (EBIX), up 7.5%... Revolution Lighting (RVLT), up 12%. ALSO HIGHER: Liberty Media (LMCA), up 7% after announcing plans for two new tracking stock groups, saying its offer for Sirius XM (SIRI) is no longer applicable... Achillion (ACHN), up 4.4% after announcing clinical results for ACH-3102. DOWN AFTER EARNINGS: Aeropostale (ARO), down 15%... Fuel Systems (FSYS), down 13%. ALSO LOWER: Sirius XM, down 1.5% after Liberty Media said its offer for Sirius was no longer applicable... General Mills (GIS), down 3.2% after warning on Q3 earnings... Plug Power (PLUG), down 3% following downgrades at Cowen and Roth Capital... Body Central (BODY), down 10% after to delay filing 10-K... Zogenix (ZGNX), down 7.4% following report that Senator Manchin introduced a bill to ban Zohydro.
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
16:22 EDTZGNXRA Capital Management reports 7.5% passive stake in Zogenix
Subscribe for More Information
13:36 EDTAROAeropostale signs license agreement with Himatsingka America
Aeropostale announced a domestic licensing agreement for home textiles with Himatsingka America. Under the licensing agreement, Himatsingka will design, manufacture and distribute home textiles such as bedding and bath linens using the Aeropostale label for department stores, big box retailers and wholesale channels across North America. Under this agreement, Aeropostale's expanded home collection is expected to be available during the Back to School 2016 season.
October 7, 2015
16:22 EDTSIRISirius XM, NFL announce six-year extension of satellite radio agreement
Subscribe for More Information
October 6, 2015
10:43 EDTACHNOptions with decreasing implied volatility
Subscribe for More Information
October 5, 2015
16:28 EDTZGNXGreat Point raises passive stake in Zogenix to 5.93%
15:32 EDTGISGeneral Mills issues voluntary recall of Cheerios, Honey Nut Cheerios
General Mills is voluntarily recalling several days of production of Cheerios and Honey Nut Cheerios cereal produced at its Lodi, California facility on certain dates in July of this year because of an undeclared allergen - wheat - with potential adverse health effects. Because this recall relates to an undeclared allergen, this is a Class I product recall. Cheerios and Honey Nut Cheerios produced on these dates at the company's Lodi, California facility are being recalled because an isolated incident resulted in wheat flour being inadvertently introduced into the gluten free oat flour system at its Lodi facility. As a result, the products may contain an undeclared allergen - wheat - in products labeled as gluten-free. General Mills will recall and retrieve affected cereals produced on those dates from customer warehouses and store shelves. Consumers with wheat allergies, celiac disease or gluten intolerance should not consume products bearing the affected code dates and should contact General Mills for a replacement or full refund. This voluntary recall includes four days production of original (yellow box) Cheerios, and thirteen days of production of Honey Nut Cheerios at its Lodi, California facility with the following "BETTER IF USED BY" code dates and the plant code LD which indicates the product was produced at Lodi, California.
October 2, 2015
15:17 EDTGISGeneral Mills voluntarily recalls Cascadian Farm Cut Green Beans
Subscribe for More Information
September 30, 2015
19:51 EDTSIRISirius XM blames T-Mobile towers for signal loss, WSJ says
Subscribe for More Information
08:07 EDTZGNXZogenix reports positive top-line results from Relday Phase 1b clinical trial
Zogenix announced positive top-line pharmacokinetic results from its Phase 1b multi-dose clinical trial of Relday, a proprietary, once-monthly subcutaneous investigational formulation of risperidone for the treatment of schizophrenia. If approved, Relday has the potential to be the first subcutaneous antipsychotic product that achieves therapeutic drug levels on the first day of administration, allows for once-monthly dosing and does not require reconstitution. Zogenix has retained Locust Walk Partners of Cambridge, MA, a transaction advisory firm for life sciences companies, to provide transaction advisory and support services for Relday, and has now initiated efforts to secure a global strategic development and commercialization partner for Relday. The Phase 1b multi-dose parallel group clinical trial enrolled 60 subjects comprised of three cohorts of patients receiving four monthly injections of Relday, at dose levels of either 60, 90 or 120 mg of risperidone per month. A fourth cohort received five bi-weekly intramuscular injections of Risperdal Consta. Risperdal Consta requires oral supplementation for the first three weeks following dosing initiation, and requires at least four doses to reach steady state. The results for Relday demonstrated that risperidone plasma concentrations in the therapeutic range were achieved on the first day of dosing, reached steady state levels following the second dose and consistently maintained therapeutic levels throughout the four-month period. In addition, dose proportionality was confirmed across the dose range intended for clinical practice (60 to 120 mg). Relday was generally safe and well-tolerated, with results consistent with the profile of risperidone and the Company's previous Phase 1 single-dose clinical trial.
September 29, 2015
19:24 EDTAROAeropostale says considering reverse stock split to meet listing requirement
Subscribe for More Information
16:09 EDTAROAeropostale receives NYSE listing notice
Subscribe for More Information
09:33 EDTULTAULTA Beauty downgraded to Peer Perform from Outperform at Wolfe Research
09:30 EDTEBIXEY, Ebix partner to delivery digital solutions to India, Bangladesh
Subscribe for More Information
September 28, 2015
09:22 EDTGISGeneral Mills management to meet with JPMorgan
Subscribe for More Information
September 25, 2015
07:33 EDTEBIXEbix's PPL selected by London Broking Firms
Ebix announced that senior executives of 16 broking firms representing more than 80% of business placed in the London market have made a formal commitment to electronic placement of insurance through the Placing Platform Limited electronic placing platform, powered by Ebix's technology. The communique, signed through the auspices of the London & International Insurance Brokers' Association board, was revealed by Steve Hearn, chairman of the London Market Group, at a market-wide forum held by the trade body yesterday, in London. An open letter signed by the executives said they were committed to all risks being captured and processed electronically. The Liiba commitment letter detailed the introduction of a single platform to facilitate electronic support for placing, with the PPL board being provided with appropriate finance and authorization to enter into a contract, for a full market roll out beginning January 2016. Ebix confirmed that it is presently on target to launch the service on Jan.1, 2016.
06:48 EDTGISCereal makers tweak recipes in emerging markets, WSJ says
Subscribe for More Information
September 24, 2015
05:08 EDTSIRIStocks with implied volatility movement; SIRI CLF
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use